Vision & Strategy

Vision & Strategy

Astellas stands on the forefront of healthcare change, turning innovative science into value for patients.

Corporate Social Sustainability

Astellas upholds our corporate responsibility to contribute to the sustainable development of society through a variety of dedicated programs.

Careers

man and woman in lobby
Want to join our team? Search current career opportunities or send us your resumé.

News

Canada
News / Press Releases
VEOZAH® (fezolinetant film-coated tablets) Receives Health Canada Approval as First and Only Non-hormonal Treatment for Vasomotor Symptoms (VMS) Associated with Menopause
Read More
Canada
News / Press Releases
Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy
Read More
Canada
News / Press Releases
XTANDI® (enzalutamide) Receives Health Canada Approval as the First and Only Treatment for High-Risk Patients with Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC)
Read More
Global
News / Stories
Astellas Uses C3 Prize to Look Beyond Treatments in Fostering Innovation in Cancer Care
Read More
Global
News / Stories
Local Contribution. Global Impact.
Read More
View All >>
Canada
News / Press Releases
VEOZAH® (fezolinetant film-coated tablets) Receives Health Canada Approval as First and Only Non-hormonal Treatment for Vasomotor Symptoms (VMS) Associated with Menopause
Read More
Canada
News / Press Releases
Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy
Read More
Canada
News / Press Releases
XTANDI® (enzalutamide) Receives Health Canada Approval as the First and Only Treatment for High-Risk Patients with Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC)
Read More
View All >>